Genetic Testing and Health Insurance: Where Coverage Stands Today
Bupa UK recently announced the launch of three DNA/genomic tests, focused on medication response, cancer predisposition, and mental health risk, as it expands its suite of My Genomic Health tests. These tests are not covered under Bupa Global health insurance plans. Instead, members must pay out of pocket – roughly £200 per test. Despite the claim (which might be true) that such tests can reduce long-term healthcare costs by avoiding ineffective treatments or enabling earlier intervention, the lack of coverage sends a mixed message.
What is Genomics?
Genomics is the study of a person’s complete set of DNA – including all of their genes – and how those genes interact with each other and with the environment. Unlike genetic testing that may look at a single gene or mutation, genomics takes a broader view, helping to identify patterns and risks across the entire genome. In healthcare, genomics is increasingly used to predict disease risk, detect conditions earlier, and personalize treatment plans. According to Bupa, genomics can also guide screening and prevention strategies based on a person’s inherited genetic profile.
What is Pharmacogenomics?
Pharmacogenomics is a branch of genomics that focuses specifically on how a person’s genes affect their response to medications. By analyzing specific genetic variants, pharmacogenomic testing can help predict which drugs are likely to be most effective – or cause adverse reactions – for an individual. As Bupa explains, this kind of testing is particularly useful for commonly prescribed medications such as antidepressants, painkillers, statins, and contraceptives. While pharmacogenomics is a form of DNA testing, its goal is not to assess disease risk, but to guide personalized prescribing and improve treatment outcomes.
Disconnect Between Value and Access
If the tests are truly cost-saving and medically valuable, why aren’t they included in the benefit structure? This disconnect highlights a common challenge with healthcare innovation – the lag between what is marketed as a breakthrough and what is actually reimbursed. In many ways, this move feels more like an upsell than a genuine push toward preventive healthcare.
What Are Other Insurers Doing?
Some international private medical insurance (IPMI) providers are starting to include genetic testing under certain conditions. For example, some plans cover genetic cancer screenings when medically indicated, or pharmacogenomic testing when tied to psychiatric treatment. But these are still the exception rather than the norm. Most DNA-based services remain outside standard coverage and require prior approval or self-funding.
Preventive Care is Expanding – But Unevenly
Genetic testing is part of a broader shift toward predictive, personalized care. Mental health screening tools, digital risk assessments, and cancer check-ups are increasingly built into wellness benefits or covered under outpatient plans. However, reimbursement models haven’t caught up with the speed of innovation, especially for tests that are not yet standard of care.
What This Means for Employers
At One World Cover, we help clients navigate the grey area between innovation and actual coverage. When new tests or tools = like DNA screening – enter the market, they’re often promoted as cost-saving or transformative. But unless those tools are embedded into the health insurance policy, there’s no guarantee of access or reimbursement.
Our job is to cut through the marketing, assess what’s truly covered, and help clients ask the right questions. We also advocate for plan designs that balance innovation with real-world value – because investing in meaningful prevention only makes sense when your team can actually use the benefit.
As predictive diagnostics like pharmacogenomic or cancer risk testing continue to evolve, we’ll continue pushing insurers to move from pilot programs and upsells toward inclusion in standard cover. That’s how prevention becomes protection – not just a product.
To learn more please get in touch: [email protected] or click here to contact us.
